JP2015521607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521607A5 JP2015521607A5 JP2015517621A JP2015517621A JP2015521607A5 JP 2015521607 A5 JP2015521607 A5 JP 2015521607A5 JP 2015517621 A JP2015517621 A JP 2015517621A JP 2015517621 A JP2015517621 A JP 2015517621A JP 2015521607 A5 JP2015521607 A5 JP 2015521607A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- antibody
- administered
- treatment
- morphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 35
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 26
- 229960005181 morphine Drugs 0.000 claims 13
- 238000001802 infusion Methods 0.000 claims 8
- 238000001990 intravenous administration Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229960004497 dinutuximab Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/061618 WO2013189516A1 (en) | 2012-06-18 | 2012-06-18 | Method for treating a gd2 positive cancer |
| EPPCT/EP2012/061618 | 2012-06-18 | ||
| PCT/EP2012/064970 WO2013189554A1 (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521607A JP2015521607A (ja) | 2015-07-30 |
| JP2015521607A5 true JP2015521607A5 (OSRAM) | 2015-09-17 |
| JP6283665B2 JP6283665B2 (ja) | 2018-02-21 |
Family
ID=46317406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517621A Active JP6283665B2 (ja) | 2012-06-18 | 2012-07-31 | Ｇｄ２陽性癌を治療するための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10294305B2 (OSRAM) |
| JP (1) | JP6283665B2 (OSRAM) |
| KR (1) | KR101927118B1 (OSRAM) |
| CN (1) | CN104487088A (OSRAM) |
| AP (1) | AP2014008129A0 (OSRAM) |
| AU (1) | AU2012383254B2 (OSRAM) |
| BR (1) | BR112014031806A8 (OSRAM) |
| CA (1) | CA2876529C (OSRAM) |
| EA (1) | EA038188B1 (OSRAM) |
| HK (1) | HK1203375A1 (OSRAM) |
| IL (1) | IL235696A0 (OSRAM) |
| MX (1) | MX377157B (OSRAM) |
| SG (2) | SG11201408487WA (OSRAM) |
| WO (2) | WO2013189516A1 (OSRAM) |
| ZA (1) | ZA201407961B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861251A1 (en) | 2012-06-18 | 2015-04-22 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| NZ720273A (en) | 2013-11-21 | 2022-02-25 | Apeiron Biologics Ag | Preparations and methods for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| PT3154583T (pt) * | 2014-06-04 | 2021-03-24 | Biontech Res And Development Inc | Anticorpos monoclonais humanos para o gangliósido gd2 |
| US10329323B2 (en) | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| WO2019059771A2 (en) * | 2017-09-21 | 2019-03-28 | Umc Utrecht Holding B.V. | ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| WO2020165402A1 (en) | 2019-02-14 | 2020-08-20 | Westfälische Wilhelms-Universität Münster | Gd2-upregulation by ezh2 inhibition in cancer therapy |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| JP7505784B2 (ja) * | 2019-08-01 | 2024-06-25 | 国立大学法人三重大学 | Ｇｄ２結合性分子 |
| WO2021108670A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| JP2023532753A (ja) | 2020-07-06 | 2023-07-31 | イーユーエスエー ファーマ （ユーケー） リミテッド | Ｇｄ２陽性がんを治療するための方法 |
| EP4116330A1 (en) * | 2021-07-05 | 2023-01-11 | Trion Research GmbH | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| WO2023280880A1 (en) * | 2021-07-05 | 2023-01-12 | Trion Research Gmbh | Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP4194471A1 (en) * | 2021-12-10 | 2023-06-14 | Y-Mabs Therapeutics, Inc. | Anti-gd2 administration regimen |
| GB202307103D0 (en) | 2023-05-12 | 2023-06-28 | Prinses Maxima Centrum Voor Kinderoncologie B V | Method for detecting a GD2 positive cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| KR20030074693A (ko) * | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| DK1572748T3 (da) * | 2002-12-17 | 2010-08-23 | Merck Patent Gmbh | Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2 |
| EP1706428B1 (en) | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Anti-cancer antibodies with reduced complement fixation |
| JP4860702B2 (ja) | 2005-10-21 | 2012-01-25 | エフ．ホフマン−ラ ロシュ アーゲー | ポリペプチドのリコンビナント発現のための方法 |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| EP2310416A1 (en) | 2008-06-30 | 2011-04-20 | Morphotek, Inc. | Anti-gd2 antibodies and methods and uses related thereto |
| AU2011268110B2 (en) * | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| US8435972B2 (en) * | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP2861251A1 (en) | 2012-06-18 | 2015-04-22 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| NZ720273A (en) | 2013-11-21 | 2022-02-25 | Apeiron Biologics Ag | Preparations and methods for treating a gd2 positive cancer |
| US9840566B2 (en) * | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
-
2012
- 2012-06-18 WO PCT/EP2012/061618 patent/WO2013189516A1/en not_active Ceased
- 2012-07-31 AP AP2014008129A patent/AP2014008129A0/xx unknown
- 2012-07-31 SG SG11201408487WA patent/SG11201408487WA/en unknown
- 2012-07-31 WO PCT/EP2012/064970 patent/WO2013189554A1/en not_active Ceased
- 2012-07-31 BR BR112014031806A patent/BR112014031806A8/pt not_active Application Discontinuation
- 2012-07-31 EA EA201500019A patent/EA038188B1/ru unknown
- 2012-07-31 SG SG10201610532QA patent/SG10201610532QA/en unknown
- 2012-07-31 AU AU2012383254A patent/AU2012383254B2/en active Active
- 2012-07-31 CN CN201280074061.1A patent/CN104487088A/zh active Pending
- 2012-07-31 KR KR1020147033790A patent/KR101927118B1/ko active Active
- 2012-07-31 HK HK15103941.7A patent/HK1203375A1/xx unknown
- 2012-07-31 MX MX2014013858A patent/MX377157B/es active IP Right Grant
- 2012-07-31 CA CA2876529A patent/CA2876529C/en active Active
- 2012-07-31 JP JP2015517621A patent/JP6283665B2/ja active Active
-
2014
- 2014-02-18 US US14/182,776 patent/US10294305B2/en active Active
- 2014-10-31 ZA ZA2014/07961A patent/ZA201407961B/en unknown
- 2014-11-13 IL IL235696A patent/IL235696A0/en unknown
-
2017
- 2017-09-11 US US15/700,538 patent/US11447565B2/en active Active
-
2019
- 2019-04-04 US US16/375,022 patent/US20200055953A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/933,295 patent/US20230340148A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521607A5 (OSRAM) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| JP2015527318A5 (OSRAM) | ||
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| JP2012102122A5 (OSRAM) | ||
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| JP2014169326A5 (OSRAM) | ||
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2016528162A5 (OSRAM) | ||
| JP2014533279A5 (OSRAM) | ||
| FI3845245T3 (fi) | Seerumin fosfaatin efektiivinen ja tehokas säätely optimaalista luunmuodostusta varten | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| JP2019517549A5 (OSRAM) | ||
| NZ582619A (en) | Humanized anti-fgf19 antagonists and methods using same | |
| JP2016539122A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| JP2018512402A5 (OSRAM) | ||
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| NZ720273A (en) | Preparations and methods for treating a gd2 positive cancer | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| EA202090558A1 (ru) | Схемы лечения |